Article
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.
Signal transduction and targeted therapy - 15 Oct 2021
Jiang Tao, Wang Pingyang, Zhang Jie, Zhao Yanqiu, Zhou Jianying, Fan Yun, Shu Yongqian, Liu Xiaoqing, Zhang Helong, He Jianxing, Gao Guanghui, Mu Xiaoqian, Bao Zhang, Xu Yanjun, Guo Renhua, Wang Hong, Deng Lin, Ma Ningqiang, Zhang Yalei, Feng Hui, Yao Sheng, Wu Jiarui, Chen Luonan, Zhou Caicun, Ren Shengxiang
Abstract excerpt
This multicenter phase-II trial aimed to investigate the efficacy, safety, and predictive biomarkers of toripalimab plus chemotherapy as second-line treatment in patients with EGFR-mutant-advanced NSCLC. Patients who failed from first-line EGFR-TKIs and did not harbor T790M mutation were enrolled. Toripalimab plus carboplatin and pemetrexed were administrated every three weeks for up to six cycles, followed by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.